PMID- 34610623 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20221007 IS - 1728-7731 (Electronic) IS - 1726-4901 (Linking) VI - 84 IP - 12 DP - 2021 Dec 1 TI - Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer. PG - 1139-1144 LID - 10.1097/JCMA.0000000000000629 [doi] AB - BACKGROUND: Cisplatin-based chemotherapy (CBC) is highly efficacious for advanced cervical cancer; its efficacy can be enhanced by combining with 15 mg/kg (standard dose) bevacizumab (BEV). However, this standard dose is associated with various adverse events (AEs). Therefore, in this retrospective study, we analyzed the survival outcomes and AEs in patients with advanced or recurrent cervical cancer treated with CBC in combination with BEV 7.5 mg/kg. METHODS: Registered patient data were retrieved between October 2014 and September 2019, and 64 patients with advanced or recurrent cervical cancer treated with CBC + BEV (n = 21) or CBC alone (n = 43) were analyzed. The primary endpoints were progression-free survival (PFS) and overall survival (OS); the secondary endpoints were the frequency and severity of AEs. The Cox proportional-hazards model was applied to explore prognostic factors associated with PFS and OS. RESULTS: The 1-, 2-, and 3-year PFS rates (95% CI) were 36.24% (22.0-50.5), 20.7% (9.8-34.2), and 17.7% (7.7-31.1) for the CBC group; and 71.4% (47.1-86.0), 51.0% (27.9-70.1), and 51.0% (27.9-70.1) for the CBC + BEV group, respectively. The 1-, 2-, and 3-year OS rates were 62.6% (46.4-75.18), 32.4% (18.8-46.9), and 23.2% (11.2-37.6) for the CBC group; and 85.7% (61.9-95.1), 66.6% (42.5-82.5), and 55.5% (27.1-76.7) for the CBC + BEV group, respectively. The CBC + BEV group presented higher PFS and OS rates, p = 0.003 and p = 0.005, respectively. Proteinuria (6 vs 9, p = 0.025) and hypertension (0 vs 10, p < 0.001) were less common, but anemia was more common in the CBC group (35 vs 11, p = 0.021). CONCLUSION: Overall, CBC + BEV significantly improved the PFS and OS compared with CBC alone. CBC + BEV also prevents severe AEs and hence is an efficacious and safe therapeutic option. CI - Copyright (c) 2021, the Chinese Medical Association. FAU - Liu, Chia-Hao AU - Liu CH AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Kung, Yen-Hsuan AU - Kung YH AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Chien-Fu Lin, Jeff AU - Chien-Fu Lin J AD - Department of Statistics, National Taipei University, Taipei, Taiwan, ROC. AD - Department of Orthopedic Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, ROC. FAU - Chuang, Chi-Mu AU - Chuang CM AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Wu, Hua-Hsi AU - Wu HH AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Jiang, Ling-Yu AU - Jiang LY AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Shih, Ying-Chu AU - Shih YC AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Wang, Peng-Hui AU - Wang PH AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, ROC. FAU - Chen, Yi-Jen AU - Chen YJ AD - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Department of Obstetrics and Gynecology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. LA - eng PT - Journal Article PL - Netherlands TA - J Chin Med Assoc JT - Journal of the Chinese Medical Association : JCMA JID - 101174817 RN - 0 (Antineoplastic Agents) RN - 0 (Antineoplastic Agents, Immunological) RN - 2S9ZZM9Q9V (Bevacizumab) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Aged MH - Antineoplastic Agents/*therapeutic use MH - Antineoplastic Agents, Immunological/*administration & dosage/*therapeutic use MH - Bevacizumab/*administration & dosage/*therapeutic use MH - Cisplatin/*therapeutic use MH - Female MH - Humans MH - Middle Aged MH - Neoplasm Recurrence, Local/*drug therapy MH - Retrospective Studies MH - Treatment Outcome MH - Uterine Cervical Neoplasms/*drug therapy/pathology COIS- Conflicts of interest: Dr. Peng-Hui Wang and Dr. Yi-Jen Chen, editorial board members at Journal of the Chinese Medical Association, have no roles in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article. EDAT- 2021/10/06 06:00 MHDA- 2022/02/08 06:00 CRDT- 2021/10/05 20:21 PHST- 2021/10/06 06:00 [pubmed] PHST- 2022/02/08 06:00 [medline] PHST- 2021/10/05 20:21 [entrez] AID - 02118582-202112000-00012 [pii] AID - 10.1097/JCMA.0000000000000629 [doi] PST - ppublish SO - J Chin Med Assoc. 2021 Dec 1;84(12):1139-1144. doi: 10.1097/JCMA.0000000000000629.